Pyrrolidine derivatives as NK3 receptor antagonists
申请人:Hoffmann-La Roche Inc.
公开号:US08318759B2
公开(公告)日:2012-11-27
The present invention relates to a compounds of formula I
wherein A, Ar, R, R2, R3, R4, p, and o are as defined in the specification and claims or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).
PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
申请人:Knust Henner
公开号:US20100210659A1
公开(公告)日:2010-08-19
The present invention relates to a compounds of formula I
wherein A, Ar, R, R2, R3, R4, p, and o are as defined in the specification and claims or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).